翰森製藥
HANSOH PHARMA

# Hansoh Pharmaceutical Group Company Limited
# 翰森製藥集團有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3692)**

## TERMINATION OF THE POST-IPO RSU SCHEME AND PROPOSED ADOPTION OF THE 2026 SHARE SCHEME

The board of directors (the "**Board**") of Hansoh Pharmaceutical Group Company Limited (the "**Company**" and together with its subsidiaries, the "**Group**") hereby announces that, on April 28, 2026, the Board has resolved to terminate the Post-IPO RSU Scheme of the Company adopted on May 27, 2019 (the "**Existing RSU Scheme**"), and proposed to seek approval from the shareholders of the Company (the "**Shareholder(s)**") at the forthcoming annual general meeting of the Company (the "**AGM**") for the adoption of the 2026 Share Scheme (the "**New Share Scheme**"). The termination date of the Existing RSU Scheme shall take effect on the date of adoption of the New Share Scheme.

### TERMINATION OF THE EXISTING RSU SCHEME

The Existing RSU Scheme was adopted by way of a resolution of the Shareholders on May 27, 2019 and is valid and effective for the period of 10 years commencing on June 14, 2019, being the listing date of the shares of the Company (the "**Scheme Period**"). According to the terms of the Existing RSU Scheme, the Existing RSU Scheme may be terminated at any time prior to the expiry of the Scheme Period by the Board. No further awards shall be granted after the Existing RSU Scheme is terminated but in all other respects the provisions of the Existing RSU Scheme shall remain in full force and effect. All awards granted under the Existing RSU Scheme prior to such termination that have not yet vested as at the date of the termination shall remain valid.

The Board is of the view that, following the amendments to Chapter 17 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") which have taken effect on January 1, 2023, the termination of the Existing RSU Scheme and the proposed adoption of the New Share Scheme align with market practice and are conducive to the long-term objectives of the Group as a whole.

### PROPOSED ADOPTION OF THE NEW SHARE SCHEME

The New Share Scheme enables the Company to grant awards in the form of RSUs and options, and its purpose is (a) to recognize the contributions by the eligible participants and give incentives to them in order to retain them for the continual operation and development of the Group; and (b) to attract suitable and skilled personnel to strive for the future development of the Group, with a view to achieving the objectives of increasing the value of the Company and aligning the interests of the selected participants directly to the Shareholders through ownership of shares of the Company.

The New Share Scheme is intended to be funded by new shares, existing shares and/or treasury shares of the Company. Therefore, the New Share Scheme will constitute a share scheme involving issue of new shares by the Company and the terms and conditions of which are required to comply with Chapter 17 of the Listing Rules.

The adoption of the New Share Scheme is subject to, among other things, (i) the passing of ordinary resolutions at the AGM, and (ii) the listing committee of the Stock Exchange granting the approval for the listing of, and permission to deal in, the new shares to be issued and allotted pursuant to all the awards to be granted under the New Share Scheme.

The Company will convene and hold the AGM to consider and, if thought fit, approve, among other matters, the proposed adoption of the New Share Scheme. A circular containing, among other things, the proposed adoption of the New Share Scheme and the notice of the AGM will be published in due course.

By Order of the Board
**Hansoh Pharmaceutical Group Company Limited**
**Zhong Huijuan**
*Chairlady*

Hong Kong, April 28, 2026

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia as independent non-executive directors.*